Antihypertensive Effect of the ACE Inhibitory Peptides Derived from Bovine Casein in Rats
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
In order to investigate the blood pressure-lowering effect of angiotensin I-converting enzyme inhibitory peptides (ACEI) derived from bovine casein, spontaneously hypertensive rats (SHR) were used as the animal model. After 30 days of sample administration, the blood pressure, heart rate, serum and urine of rats were examined. Compared with the model control group, the systolic blood pressure and heart rate of the ACE inhibitory peptides high- and low-dose groups and the positive control group were 175, 175, and 172 mm Hg, respectively, with the differences being statistically significant (p<0.01); the concentration of calcitonin gene-related peptide (CGRP) in the ACE inhibitory peptides high-dose group increased to 10.09 pg/mL, with the change being statistically significant (p<0.05); the concentrations of total calcium (TCa), endothelin-1 (ET1), blood glucose (GLU), total cholesterol (CHOL), high density lipoprotein cholesterol (HDL-C) and blood uric acid (UA) in the ACE inhibitory peptides high-dose group decreased significantly (to 2.06 mmol/L, 8.69 pg/mL, 6.41 mmol/L, 1.13 mmol/L, 0.29 mmol/L and 108.20 μmol/L, respectively), with the changes being statistically significant (p<0.05). The results showed that under the experimental conditions, ACE inhibitory peptides not only relieved the fast heartbeat and lowered significantly blood pressure in rats, but also help to improve the serum biochemical indices and renal function indices of rats with renovascular hypertension while exhibiting a certain monitoring effect on the blood sugar, blood uric acid and cholesterol. ACE inhibitory peptides may lower blood pressure by increasing blood CGRP, inhibiting ETI, and lowering blood calcium level.
